Primary purpose of the study is to see if rifaximin can improve the balance of bacteria within the gut, which has been shown to improve transplant outcomes. It will also assess whether rifaximin can reduce the risk of infection in blood/marrow transplant (BMT).
This study is for patients who will be having a blood/marrow transplant (BMT) to treat leukemia, lymphoma or other cancer of the blood. The blood or marrow cells will come from another person (donor)-allogeneic BMT. Bacterial infections and acute graft versus host disease (AGVHD) are frequent complications of allogeneic BMT. Bacterial infections sometimes happen because injury to the gut during transplant allows gut bacteria to cross the injured gut barrier and get to the blood. AGVHD happens when certain white blood cells, called T-cells, in the donor cells (the graft) attack the patient's body. Primary purpose of the study is to see if rifaximin can improve the balance of bacteria within the gut, which has been shown to improve transplant outcomes. It will also assess whether rifaximin can reduce the risk of infection in blood/marrow transplant (BMT).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
26
Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
Children's Healthcare of Atlanta
Atlanta, Georgia, United States
Alterations to microbiome diversity in children treated with rifaximin compared to the historical cohort.
Composition will be assessed using 16S RNA sequencing. The Shannon index will be calculated for quantification of bacterial diversity.
Time frame: Period between the start of the preparative regimen and day 28 post transplant
Rates of BSI pathogen infection/colonization frequency during the treatment period compared to the historical cohort.
Results of the GI pathogen panel, a test incorporated into routine patient care detecting DNA or RNA of 22 common viral, bacterial, and parasitic organisms, will provide a second assessment through molecular detection of the presence of common organisms associated with intestinal dysbiosis.
Time frame: Period between the start of the preparative regimen and day 28 post transplant
Transplant related mortality (TRM)
Number of deaths occurring in continuous complete remission.
Time frame: Period between the start of the preparative regimen and day 28 post transplant
Number of patients with Acute GVHD
Early onset (before day 100) acute GVHD (including all grades, and stratified by grades) will be assessed according to the Blood and Marrow Transplant Clinical Trials Network Manual version 2, 2005, section 1 using the NIH consensus criteria
Time frame: Period between the start of the preparative regimen and day 100 post transplant
Number of patients with Chronic GVHD including overlap syndrome
Chronic GVHD including overlap syndrome, will be assessed according to the 2014 NIH consensus criteria.
Time frame: Period between the start of the preparative regimen and year 5 post-transplant.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of patients with other Infections
Other Infections will be defined in accordance with the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures
Time frame: Period between the start of the preparative regimen and day 28 post transplant
Number of patients with relapse free survival at 1 year
Survival without relapse of underlying malignancy.
Time frame: Period between the start of the preparative regimen and year 1 post-transplant.
Overall number of patients survived at 1 year
Survival with or without relapse of underlying malignancy.
Time frame: Period between the start of the preparative regimen and year 1 post-transplant.